Laprituximab Biosimilar - Research Grade

Human

EGFR

>1mg/ml

IgG1 - kappa

CHO Cells

Bulk Anti-Human EGFR (EGFR.1) Antibody (ICH1021), Cetuximab Biosimilar - Research Grade (ICH4004), Matuzumab Biosimilar - Research Grade (ICH4007), Nimotuzumab Biosimilar - Research Grade (ICH4008), Panitumumab Biosimilar - Research Grade (ICH4028), Zalutumumab Biosimilar - Research Grade (ICH5116), Necitumumab Biosimilar - Research Grade (ICH5121), Depatuxizumab Biosimilar - Research Grade (ICH5294), Becotatug Biosimilar - Research Grade (ICH5378), Demupitamab Biosimilar - Research Grade (ICH5473), Futuximab Biosimilar - Research Grade (ICH5560), Imgatuzumab Biosimilar - Research Grade (ICH5600), Losatuxizumab Biosimilar - Research Grade (ICH5657), Modotuximab Biosimilar - Research Grade (ICH5691), Pimurutamab Biosimilar - Research Grade (ICH5774), Serclutamab Biosimilar - Research Grade (ICH5853), Tomuzotuximab Biosimilar - Research Grade (ICH5933)

https://www.imgt.org/mAb-DB/

ICH3002

P00533

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-EGFR antibody laprituximab, supplied strictly for research use only. It is a human IgG1/kappa immunoglobulin engineered to bind the epidermal growth factor receptor (EGFR, UniProt P00533), reproducing the antigen-binding specificity of the originator molecule while carrying no drug conjugate or therapeutic formulation. It is not the clinical drug and is not intended for human or veterinary use. The preparation is useful as a defined, reproducible binding reagent for EGFR-focused workflows: as a positive control or reference antibody in receptor-binding and neutralisation assays, as a benchmarking tool during antibody or ADC development against EGFR, and as a component in in-vitro cell-based and preclinical model systems. It is offered at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and is available in bulk milligram-to-gram quantities to support screening campaigns, assay standardisation, and reagent-hungry experimental pipelines where lot consistency and cost efficiency matter. EGFR (epidermal growth factor receptor; ErbB1/HER1, UniProt P00533) is a single-pass transmembrane receptor tyrosine kinase of the ErbB family. Ligands such as EGF and TGF-alpha bind its extracellular domain, driving receptor homodimerisation or heterodimerisation with other ErbB members (notably HER2/ErbB2). Dimerisation activates the intracellular kinase domain, triggering trans-autophosphorylation of cytoplasmic tyrosines and downstream signalling through the RAS-RAF-MEK-ERK, PI3K-AKT, and STAT pathways to promote proliferation, survival, migration, and differentiation. EGFR overexpression, activating mutations, and gene amplification are recurrent drivers in epithelial cancers, including non-small-cell lung, colorectal, and head-and-neck carcinomas, making the receptor a heavily studied oncology target for antibodies and small-molecule kinase inhibitors.

Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, Epidermal growth factor receptor, ERBB, ERBB1, HER1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks